Nov 26, 2024 15:50 JST

Source: Eisai

Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan

TOKYO, Nov 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd. announced today that Eisai has entered into a research collaboration agreement with the National Center of Neurology and Psychiatry to conduct apolipoprotein E (APOE) genetic testing in the dementia research and development program, “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease” (“AD-DMT Registry”). The research will be implemented by the Japan Agency forMedical Research and Development (AMED), with NCNP as the lead research institution.

The APOE gene is known to be a risk factor for the onset of Alzheimer’s disease and is also associated with the frequency of amyloid-related imaging abnormalities (ARIA) in anti-amyloid β antibody treatments such as lecanemab (LEQEMBI®).(1)

In Japan, at present, APOE genetic testing is not available for routine clinical practice under National Health Insurance. For thisreason, by using APOE genetic information collected in the AD-DMT Registry, Eisai and NCNP can further study the relationship between the APOE genotype and the safety and efficacy of treatment with lecanemab.

Based on this research collaboration agreement with NCNP, Eisai will cover the cost of the APOE genetic testing conducted in the AD-DMT Registry. The findings, along with data collected from the lecanemab-specific post-marketing surveillance (all-casesurveillance), will be part of the reexamination of lecanemab’s application by the Japanese Pharmaceuticals and MedicalDevices Agency (PMDA) to ensure the label reflects the latest scientific understanding with the goal of improving patientoutcomes.

Eisai and Biogen Japan will continue to contribute to the advancement of Alzheimer’s disease treatment through ongoing collaboration with academia.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. (U.S.)co-commercializing and co-promoting the product and Eisai having final decision- making authority. In Japan, Eisai and Biogen Japan will co-promote lecanemab, with Eisai distributing the product as the Marketing Authorization Holder.

(1) Foley KE and Wilcock DM (2024). Three major effects of APOEε4 on Aβ immunotherapy induced ARIA. Front. Aging Neurosci. 16:1412006. doi: 10.3389/fnagi.2024.1412006

About the “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease”

The National Center of Neurology and Psychiatry (NCNP) is the lead research institution for the dementia research and development program “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease” under the Japan Agency for Medical Research and Development (AMED). The research is being conducted with the aim of collecting clinical information and test data obtained from routine medical care using treatments including anti-amyloid β antibody drugs such as lecanemab, evaluate the efficacy and safety of these drugs, and perform blood sampling for APOE genotyping and measurement of other biomarkers in patients receiving the drugs. Some of theseresults will be reported to the participating patients, and the safety and efficacy of the drugs will be examined based on APOE genotype and other factors. Eisai plans to conduct large-scale and efficient research by sharing data of patients who have given their consent from the specific post-marketing surveillance.

For more details on AMED's dementia research and development program, please visit the AMED website.

About Eisai

Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase thebenefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim toeffectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology, Oncology and Global Health.

Theoria technologies Co., Ltd., a member of the Eisai Group, operates the dementia portal site "Theotol" (https://theotol.soudan-e65.com/), which provides easy-to-understand contents and services for the general public aboutMCI and various types of dementia, their causes, treatments, as well as caregiving methods and personal experiences. (Japanese only)

About Biogen Japan

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding ofhuman biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information on Biogen Japan that may be important to investors on our website at https://www.biogen.com/ and social media Facebook, Twitter, Instagram, YouTube, LinkedIn, LINE.

Media Contacts:

Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Biogen Japan, Ltd.
Corporate Affairs
TEL: +81-70-1501-4315
E-mail: Japan-PA@biogen.com

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
December 05 2024 10:22 JST
 
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
November 28 2024 15:26 JST
 
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
November 20 2024 10:51 JST
 
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
November 20 2024 09:24 JST
 
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
November 15 2024 16:33 JST
 
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
November 15 2024 13:31 JST
 
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
November 05 2024 10:35 JST
 
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
November 01 2024 12:56 JST
 
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
October 31 2024 12:56 JST
 
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
October 31 2024 10:33 JST
 
More Press release >>

Latest Press Release


More Latest Release >>